Analysts predict that FibroGen Inc (NASDAQ:FGEN) will announce $55.05 million in sales for the current quarter, according to Zacks. Three analysts have issued estimates for FibroGen’s earnings. The highest sales estimate is $71.30 million and the lowest is $28.84 million. FibroGen posted sales of $42.51 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 29.5%. The business is scheduled to announce its next quarterly earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that FibroGen will report full year sales of $159.88 million for the current financial year, with estimates ranging from $133.74 million to $176.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $232.33 million, with estimates ranging from $92.00 million to $365.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow FibroGen.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.15). The company had revenue of $29.00 million for the quarter, compared to analysts’ expectations of $36.48 million. FibroGen had a negative net margin of 87.84% and a negative return on equity of 24.59%. FibroGen’s revenue was down 28.6% compared to the same quarter last year.
A number of analysts have recently weighed in on FGEN shares. Leerink Swann set a $84.00 price objective on FibroGen and gave the company a “buy” rating in a research note on Monday, October 15th. ValuEngine lowered FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Zacks Investment Research lowered FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. TheStreet lowered FibroGen from a “c-” rating to a “d+” rating in a research note on Wednesday, November 21st. Finally, BidaskClub lowered FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. FibroGen presently has a consensus rating of “Buy” and an average price target of $72.25.
In other FibroGen news, SVP Pat Cotroneo sold 1,011 shares of the stock in a transaction on Monday, September 10th. The stock was sold at an average price of $57.35, for a total value of $57,980.85. Following the completion of the transaction, the senior vice president now owns 220,422 shares in the company, valued at $12,641,201.70. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Thomas B. Neff sold 30,000 shares of the stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $40.93, for a total value of $1,227,900.00. Following the completion of the transaction, the chief executive officer now owns 2,646,320 shares of the company’s stock, valued at approximately $108,313,877.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 229,773 shares of company stock valued at $11,424,203. 8.96% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the company. Trexquant Investment LP bought a new stake in FibroGen in the 3rd quarter worth about $201,000. Oppenheimer Asset Management Inc. bought a new stake in FibroGen in the 2nd quarter worth about $236,000. Pacer Advisors Inc. bought a new stake in FibroGen in the 3rd quarter worth about $246,000. Nisa Investment Advisors LLC increased its holdings in FibroGen by 1,829.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 6,174 shares of the biopharmaceutical company’s stock worth $375,000 after buying an additional 5,854 shares in the last quarter. Finally, Aperio Group LLC increased its holdings in FibroGen by 56.3% in the 2nd quarter. Aperio Group LLC now owns 7,004 shares of the biopharmaceutical company’s stock worth $438,000 after buying an additional 2,523 shares in the last quarter. Hedge funds and other institutional investors own 64.86% of the company’s stock.
NASDAQ:FGEN opened at $37.97 on Friday. The company has a market cap of $3.51 billion, a PE ratio of -21.95 and a beta of 2.13. FibroGen has a fifty-two week low of $37.64 and a fifty-two week high of $68.55. The company has a quick ratio of 6.76, a current ratio of 6.76 and a debt-to-equity ratio of 0.20.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.